CRISPR Therapeutics shows substantially deteriorating financial performance with meaningfully higher net losses despite reduced R&D spending, while increasing share count suggests significant equity financing.
The company's financial position has weakened considerably with operating losses expanding substantially even as R&D expenses declined, suggesting either increased costs in other areas or reduced collaboration revenues. The notable increase in outstanding shares from 85.8M to 96.0M indicates the company likely raised capital through equity financing, which was necessary given the higher cash burn rate.
CRISPR's financial picture reflects a challenging period with net losses expanding substantially to $581.6M despite an 11.2% reduction in R&D expenses to $284.8M, indicating pressure from other cost categories or reduced revenues. Current liabilities increased notably to $149.1M, though cash and equivalents grew modestly to $347.6M. The 12% increase in share count combined with higher losses suggests the company accessed equity markets to fund operations amid accelerating cash consumption.
Current liabilities surged 69.9% — significant near-term obligations; verify ability to meet short-term debt.
Net income declined 58.8% — review whether driven by operations, interest costs, or non-recurring items.
Capex reduced 51.9% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Cash grew 16.5% — improving liquidity position supports investment and shareholder returns.
R&D spending cut 11.2% — could signal cost discipline or concerning reduction in innovation investment.
Liabilities increased 10.8% — monitor debt-to-equity ratio and interest coverage.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →